Investigating in vitro anti-leishmanial effects of silibinin and silymarin on Leishmania major

• Autorzy: Faridnia R. , Kalani H. , Fakhar M. , Akhtari J.
• Języki publikacji: EN

Abstrakty

EN

Cutaneous leishmaniosis is an important zoonotic disease caused by various Leishmania species. The aim of this study was to investigate the effects of silibinin and silymarin on the in vitro growth and proliferation of promastigotes and amastigotes of Leishmania major compared to glucantime-treated parasites. The promastigotes and amastigotes of this parasite were treated with the two drugs, silibinin and silymarin, in several concentrations (25–100 μM). The highest effect on promastigotes was for silymarin in concentration of 100 μM with 90% and 91% death rate at hours 48 and 72, respectively. Regarding amastigotes, the highest effect at 48 hours was for silibinin in concentration of 100 μM with 35% death rate. However, at 72 hours, silymarin showed the highest effect with 63% death rate in concentration of 100 μM. The highest observed maximal 50% lethal concentration (LC₅₀) for promastigotes was for silymarin with 19.34 μM at 48 hours and 18.22 μM at 72 hours. Likewise, maximal LC₅₀ for amastigotes was for silymarin with 191 μM at 48 hours and 24.27 μM at 72 hours. Our findings demonstrated that both medications have suitable effects like Glucantime® on the parasite in vitro. Therefore, clinical assessment of the anti-leishmanial activity of silibinin and silymarin for treating the dermal lesions caused by L. major is recommended.

• Wydawca: -
• Czasopismo: Annals of Parasitology
• Rocznik: 2018
• Tom: 64
• Numer: 1
• Opis fizyczny: p.29-35,fig.,ref.

Twórcy

autor

Faridnia R.

• Department of Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Farah-Abad Road, P.O.Box 48175-866, Sari, Iran

autor

Kalani H.

• Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Hezar Jarib, P.O.Box 319, Isfahan, Iran

autor

Fakhar M.

• Department of Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Farah-Abad Road, P.O.Box 48175-866, Sari, Iran

autor

Akhtari J.

• Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Farah-Abad Road, P.O.Box 48175-866, Sari, Iran

Bibliografia

• [1] Karamian M., Motazedian M.H., Fakhar M., Pakshir K., Jowkar F., Rezanezhad H. 2008. Atypical presentation of Old-World cutaneous leishmaniasis, diagnosis and species identification by PCR. Journal of the European Academy of Dermatology and Venereology 22: 958-962. doi:10.1111/j.1468-3083.2008.02674.x
• [2] Yaghoobi-Ershadi M.R. 2016. Control of phlebotomine sand flies in Iran: a review article. Journal of Arthropod-Borne Diseases 10: 429-444.
• [3] Alvar J., Vélez I.D., Bern C., Herrero M., Desjeux P., Cano J., Jannin J., den Boer M., the WHO Leishmaniasis Control Team. 2012. Leishmaniasis world wide and global estimates of its incidence. PLoS One 7: e35671. doi:10.1371/journal.pone.0035671
• [4] Croft S.L., Olliaro P. 2011. Leishmaniasis chemotherapy – challenges and opportunities. Clinical Microbiology and Infection 17: 1478-1483. http://dx.doi.org/10.1111/j.1469-0691.2011.03630.x
• [5] den Boer M., Argaw D., Jannin J., Alvar J. 2011. Leishmaniasis impact and treatment access. Clinical Microbiology and Infection 17: 1471-1477. http://dx.doi.org/10.1111/j.1469-0691.2011.03635.x
• [6] Haldar A.K., Sen P., Roy S. 2011. Use of antimony in the treatment of leishmaniasis: current status and future directions. Molecular Biology International 2011: 571242. http://dx.doi.org/10.4061/2011/571242
• [7] Mirzaei F., Bafghi A.F., Mohaghegh M.A., Jaliani H.Z., Faridnia R., Kalani H. 2016. In vitro antileishmanial activity of Satureja hortensis and Artemisia dracunculus extracts on Leishmania major promastigotes. Journal of Parasitic Diseases 40: 1571-1574. https://doi.org/10.1007/s12639-015-0730-9
• [8] Soosaraei M., Fakhar M., Teshnizi S.H., Hezarjaribi H.Z., Banimostafavi E.S. 2017. Medicinal plants with promising antileishmanial activity in Iran: a systematic review and meta-analysis. Annals of Medicine and Surgery 21: 63-80. http://dx.doi.org/10. 1016/j.amsu.2017.07.057
• [9] Ramírez-Macías I., Marín C., Díaz J.G., Rosales M.J., Gutiérrez-Sánchez R., Sánchez-Moreno M. 2012. Leishmanicidal activity of nine novel flavonoids from Delphinium staphisagria. Scientific World Journal 2012: 203646. doi:10.1100/2012/203646
• [10] Surai P.F. 2015. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants 4: 204-247. doi:10.3390/antiox4010204
• [11] Shokri A., Akhtari J., Keighobadi M., Fakhar M., Teshnizi S.H., Emami S., Sadjjadian S. 2017. Promising antileishmanial effectiveness of doxorubicin and doxil against Leishmania major: an in vitro assay. Asian Pacific Journal of Tropical Medicine 10: 544-548. https://doi.org/10.1016/j.apjtm.2016.09.014
• [12] Cheung C.W.Y., Gibbons N., Johnson D.W., Nicol D.L. 2010. Silibinin – a promising new treatment for cancer. Anti-Cancer Agents in Medicinal Chemistry 10: 186-195. doi:10.2174/1871520611009030186
• [13] Li L., Zeng J., Gao Y., He D. 2010. Targeting silibinin in the antiproliferative pathway. Expert Opinion on Investigational Drugs 19: 243-255. http://dx.doi.org/10.1517/13543780903533631
• [14] Niño A. Camacho M. 2005. Leishmania (Viannia) braziliensis growth in vitro culture relies more on folic acid availability than Leihsmania (Leishmania) amazonensis. Memorias do Instituto Oswaldo Cruz 100: 309-310.
• [15] Shokri A., Emami S., Fakhar M., Teshnizi S.H., Keighobadi M. 2017. In vitro antileishmanial activity of novel azoles (3-imidazolylflavanones) against promastigote and amastigote stages of Leishmania major. Acta Tropica 167: 73-78. https://doi.org/10.1016/j.actatropica.2016.12.027
• [16] Post-White J., Ladas E.J., Kelly K.M. 2007. Advances in the use of milk thistle (Silybum marianum). Integrative Cancer Therapies 6: 104-109. https://doi.org/10.1177/1534735407301632
• [17] Vargas-Mendoza N., Madrigal-Santillán E., Morales-González Á., Esquivel-Soto J., Esquivel-Chirino C., García-Luna y González-Rubio M., A Gayosso-de-Lucio J., A Morales-González J. 2014. Hepatoprotective effect of silymarin. World Journal of Hepatology 6: 144-149. doi:10.4254/wjh.v6.i3.144
• [18] Ahmed-Belkacem A., Ahnou N., Barbotte L., Wychowski C., Pallier C., Brillet R., Pohl R.-T., Pawlotsky J.-M. 2010. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 138: 1112-1122. http://dx.doi.org/10.1053/j.gastro.2009.11.053
• [19] Samanta R., Pattnaik A.K., Pradhan K.K., Mehta B.K., Pattanayak S.P., Banerjee S. 2016. Wound healing activity of silibinin in mice. Pharmacognosy Research 8: 298-302. doi:10.4103/0974-8490.188880
• [20] Amin M.M., Arbid M.S. 2015. Estimation of the novel antipyretic, anti-inflammatory, antinociceptive and antihyperlipidemic effects of silymarin in Albino rats and mice. Asian Pacific Journal of Tropical Biomedicine 5: 619-623. https://doi.org/10.1016/j.apjtb.2015.05.009
• [21] Sharma M., Sehgal R., Kaur S. 2012. Evaluation of nephroprotective and immunomodulatory activities of antioxidants in combination with cisplatin against murine visceral leishmaniasis. PLoS Neglected Tropical Diseases 6: e1629. doi:10.1371/journal.pntd.0001629
• [22] Jabini R., Jaafari M.R., Vahdati Hasani F., Ghazizadeh F., Khamesipour A., Karimi G. 2015. Effects of combined therapy with silymarin and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice. Drug Research 65: 119-124. doi:10.1055/s-0034-1370914
• [23] El-Sayed N.M., Fathy G.M., Abdel-Rahman S., El-Shafei M.A. 2016. Cytokine patterns in experimental schistosomiasis mansoni infected mice treated with silymarin. Journal of Parasitic Diseases 40: 922-929. doi:10.1007/s12639-014-0606-4
• [24] Mata-Santos H.A., Lino F.G., Rocha C.C., Paiva C.N., Castelo Branco M.T.L., dos Santos Pyrrho A. 2010. Silymarin treatment reduces granuloma and hepatic fibrosis in experimental schistosomiasis. Parasitology Research 107: 1429-1434. https://doi.org/10.1007/s00436-010-2014-8
• [25] Mata-Santos HA., Dutra FF., Rocha CC., Lino FG., Xavier FR., Chinalia LA., Hossy B.H., Castelo-Branco M.T.L., Teodoro A.J., Paiva C.N., dos Santos Pyrrho A. 2014. Silymarin reduces profibrogenic cytokines and reverses hepatic fibrosis in chronic murine schistosomiasis. Antimicrobial Agents and Chemotherapy 58: 2076-2083. doi:10.1128/aac.01936-13
• [26] Kamel R.O.A. 2016. Interactions between mefloquine and the anti-fibrotic drug silymarin on Schistosoma mansoni infections in mice. Journal of Helminthology 90: 760-765. https://doi.org/10.1017/s0022149x16000018
• [27] Teichmann K., Kuliberda M., Schatzmayr G., Hadacek F., Joachim A. 2012. In vitro determination of anticryptosporidial activity of phytogenic extracts and compounds. Parasitology Research 111: 231-240. https://doi.org/10.1007/s00436-012-2824-y
• [28] Velebný S., Hrčkova G., Königová A. 2010. Reduction of oxidative stress and liver injury following silymarin and praziquantel treatment in mice with Mesocestoides vogae (Cestoda) infection. Parasitology International 59: 524-531. https://doi.org/10.1016/j.parint.2010.06.012
• [29] Velebný S., Hrčkova G.,, Kogan G. 2008. Impact of treatment with praziquantel, silymarin and/or β-glucan on pathophysiological markers of liver damage and fibrosis in mice infected with Mesocestoides vogae (Cestoda) tetrathyridia. Journal of Helminthology 82: 211-219. https://doi.org/10.1017/s0022149x08960776
• [30] Chander R., Kapoor N.K., Dhawan B.N. 1989. Hepatoprotective activity of silymarin against hepatic damage in Mastomys natalensis infected with Plasmodium berghei. Indian Journal of Medical Research 90: 472-477.

Identyfikatory

DOI

10.17420/ap6401.129